The phase 1b trial characterised them: mostly ecchymosis (bruising, in 79% of those affected) and redness (32%), all mild, and, critically, not dose-dependent
Unlike some providers, we don't increase pricing as your dosage changes
Bringing the Berberine Patch by PatchAid into your lineup gives customers a practical, plant-based solution for appetite and metabolic support
Our upcoming GLP-1 food industry report breaks down how brands are navigating this transition, including product innovation strategies, consumer behavior shifts, and where the category is heading next
The National Institutes of Health operates a searchable database at ClinicalTrials.gov for active studies involving GLP-1 medications